Effect of XRCC1 Arg399Gln Gene Polymorphism on Survival in Lymphoblastic Leukemia

Document Type : Research Articles


1 Special Surgical Disciplines Department, International Higher School of Medicine, Bishkek, Kyrgyz Republic.

2 Department of Therapy, International Higher School of Medicine, Bishkek, Kyrgyz Republic.


Introduction: The relevance of the research of the article is conditioned upon the problem of the development of molecular genetic diagnostics to determine the effectiveness of treatment for acute lymphoblastic leukemia in children. The purpose of the article is to identify the polymorphism parameters of the P53 Arg72Pro and XRCC1 Arg399Gln genes in acute lymphoblastic leukemia with criteria for determining the survival rates of sick children. Materials and methods: Methods for the study of the identified problem are the study of the medical histories of children with acute leukemia, which allowed selection of the necessary contingent of patients for further genetic study of their frozen blood, where the genomic part of deoxyribonucleic acid was isolated from the frozen blood in a standard way using molecular biological research when performing a polymerase chain reaction. Results: The article presents the results of a study that shows that in children with acute lymphoblastic leukemia, the frequency of genotypes of the XRCC1 Arg399Gln gene is variable. The most common genotypes are Arg/Gln and Arg/Arg, approximately 48% each. The Gln/Gln genotype is less common. Relapse-free survival of children with the Arg/Gln and Gln/Gln genotypes was the highest, slightly lower rates were noted with the Arg/Arg genotype. Conclusion: It was identified that the frequency of genotypes of the XRCC1 Arg399Gln gene can be a predictor of prognosis in acute lymphocytic leukemia in children, which can be considered when choosing treatment tactics, and this has practical significance for the field of medicine.


Main Subjects

Volume 24, Issue 5
May 2023
Pages 1687-1693
  • Receive Date: 23 December 2022
  • Revise Date: 20 March 2023
  • Accept Date: 16 May 2023
  • First Publish Date: 16 May 2023